The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia

The development of alpha7 nicotinic acetylcholine receptor agonists is considered a promising approach for the treatment of cognitive symptoms in schizophrenia patients. In the present studies we characterized the novel agent, (2R)-N-(6-(1H-imidazol-1-yl)-4-pyrimidinyl)-4'H-spiro[4-azabicyclo[2...

Descripción completa

Detalles Bibliográficos
Autores principales: Bristow, Linda J., Easton, Amy E., Li, Yu-Wen, Sivarao, Digavalli V., Lidge, Regina, Jones, Kelli M., Post-Munson, Debra, Daly, Christopher, Lodge, Nicholas J., Gallagher, Lizbeth, Molski, Thaddeus, Pieschl, Richard, Chen, Ping, Hendricson, Adam, Westphal, Ryan, Cook, James, Iwuagwu, Christiana, Morgan, Daniel, Benitex, Yulia, King, Dalton, Macor, John E., Zaczek, Robert, Olson, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965148/
https://www.ncbi.nlm.nih.gov/pubmed/27467081
http://dx.doi.org/10.1371/journal.pone.0159996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965148/
https://www.ncbi.nlm.nih.gov/pubmed/27467081
http://dx.doi.org/10.1371/journal.pone.0159996

Ejemplares similares